Immunitybio Inc revenue growth has been varied year-over-year.

What is IBRX's revenue growth rate?

Historical revenue data is available for Immunitybio Inc to analyze growth trends.

How fast is IBRX earnings growing?

Earnings growth data is available for Immunitybio Inc analysis.

What is IBRX's profit margin?

Profit margin data is available for Immunitybio Inc.

IBRX Revenue & Earnings Growth Analysis 2026 - Is Immunitybio Inc Growing?

Growth Summary

Immunitybio Inc (IBRX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Immunitybio Inc has achieved a revenue compound annual growth rate (CAGR) of 220.9%, while earnings have grown at 50.6% CAGR.

Latest Revenue

$14.74M

Net Income

$-413645000.00

5-Year Revenue CAGR

220.9%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Immunitybio Inc

The chart above illustrates Immunitybio Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Immunitybio Inc's business.

Profit Margin Trends

How efficiently Immunitybio Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Immunitybio Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-0.25

Current: $-0.59

EPS Estimate 2027

$-0.02

-92.1% expected growth

Price Target

$14.80

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Immunitybio Inc to continue growing earnings in the coming year. The consensus analyst rating is 4.6 based on 5 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Immunitybio Inc (IBRX) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 220.9% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Immunitybio Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.